Swiss Dental Startup vVARDIS Lists on NYSE Under Ticker VVVV
vVARDIS debuts on the New York Stock Exchange with a drill-free cavity treatment targeting the world's most common non-communicable disease.
Swiss dental health company vVARDIS began trading on the New York Stock Exchange Thursday under the ticker symbol VVVV, marking a significant milestone for a startup that has built its business around a non-invasive alternative to traditional cavity treatment.
Co-founders Dr. Haley Abivardi and Dr. Goly Abivardi launched vVARDIS with the stated goal of transforming how dental professionals and patients address tooth decay — classified by global health organizations as the world's most prevalent non-communicable disease. The company's core proposition centers on a drill-free therapeutic approach designed to treat cavities without the mechanical intervention that has defined dentistry for generations.
Read more Portillo's Faces Securities Class Action Over Investor Losses →
The public listing gives vVARDIS access to capital markets at a moment when investor appetite for health technology and preventive-care companies remains a focal point on Wall Street. By going public on the NYSE, the Abivardi-led company signals an ambition to scale its technology well beyond its current footprint and compete in a global oral-health market that affects billions of people annually.
Cavity-related disease imposes a substantial burden on healthcare systems worldwide, and companies offering alternatives to conventional restorative dentistry have increasingly drawn attention from both clinicians and institutional investors. vVARDIS enters the public markets positioning its platform as a potential standard-of-care shift rather than a niche product.
Continue reading at All Financial Services & Investing.